NEW YORK (GenomeWeb) – Molecular diagnostics maker Hibergene has closed a Series B funding round of €6.7 million ($7.2 million), the company announced today. The new funds will expand the firm's research and development programs and its international distributor network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.